An International Journal for Biomedical Sciences - Biomedicine

Serum LP ‘a’ and TG in Diabetes Mellitus
References:
1. Angelo M. Scanu and Gunther M.Fless . Lipoprotein(a):
Heterogeneity and Biological Relevance. J.Clin .Invest.
1990 ; 85:1709-1715.
2. Anthonia O Ogbera and Alfred O Azenabor .
Lipoprotein(a), C-reactive protein and some metabolic
cardiovascular risk factors in type 2 DM . Diabetology &
Metabolic syndrome 2010 ; 2:51.
3. V Mohan, R Deepa, S P Harnath, G Premalatha, M Rema
, N G Sastry et al . Lipoprotein (a) is an independent risk
factor for coronary artery disease in NIDDM patients in
South India. Diabetes Care 1998 ; 21:1819-1823.
4. G F Watts , R Map Gwilym , J Mazuri Kiewicz and
J Coltart. Independent correlation between plasma
lipoprotein(a) and angiographic coronary artery disease in
NIDDM. Diabetes Care 1995 ; 18(2): 234-236.
5. Solfrizzi V, Panza F, Colacicco AM, Capurso C, D’ lntrono
A, Torres F et al . Relation of lipoprotein(a) as coronary
risk factor to type 2 diabetes mellitus and low density lipoprotein
cholesterol in patients > or = 65 years of age (The
Italian Longitudinal study on Aging). Am J Cardiol . 2002
; 89(7) : 825-9.
6. Angelo M. Scanu , Richard M. Lawn and Kare Berg. Lipoprotein
(a) and Atheroclerosis. Ann Intern Med, 1991 ;
115(3) : 200-218.
7. Wendy Y. Craig, Louis M. Neveux, Glenn E. Palomaki,
Meghan M. Cleveland, and James E . Haddow.
Lipoprotein(a) as a risk factor for ischemic heart disease:
metanalysis of prospective studies. Clinical Chemistry
1998 ; 44 : 2301-2306.
8. Habib SS, Aslam M. High risk levels of lipoprotein(a)in
Pakistani patients with type 2 diabetes mellitus. Saudi Med
J.2003 ; 24(6): 647 – 51.
9. K.Hirata, K.Saku, S.Jimi, S.Kikuchi, H.Hamaguchi
and K.Arakawa. Serum Lp(a) concentrations and
apolipoprotein(a) phenotypes in the families of NIDDM
patients. Diabetologia. 1995 ; 38(12) :1434-42.
10. Hapizah M. Nawawia, Musilawati Muhajira , Yeo Chee
Kiana, Wan Nazaimoon Wan Mohammadb, Khalid Yusoffa,
B.A.K.Khalida. Type of diabetes and waist- hip
ratio are important determinants of serum lipoprotein (a)
levels in diabetic patients. Diabetes Res Clin Pract . 2002
; 56(3) : 221-7.
11. O’ Brien T, Nguyen T T, Marrison JM, Bailey KR, Dyek
PJ, Kott Ke BA. Lipids and lipoprotein(a) levels and coronary
artery disease in subjects with non-insulin -dependent
diabetes mellitus. Mayo Clin Proc. 1994 ; 69(5) : 430-5.
12. David L. Rainwater and Steven M. Haffner. Insulin and
2-hour glucose levels are inversely related to Lp(a) Concentrations
Controlled for LPA genotypes. Arterioscler
Thromb Vasc Biol 1998 ; 18: 1335-1341.
13. DL Rainwater, J W MacCluer, M P Stern, J L VandeBerg
and S M Haffner. Effects of NIDDM on lipoprotein (a)
concentration and apolipoprotein(a) size. Diabetes.1994 ;
43(7) : 942-946.
14. Ana Chico , Antonio Perez ,Assumpta Caixas , Jordi Ordonez
, Josep M . Pou, Albertode Leiva . Liporprotein (a)
concentrations and non -insulin -dependent diabetes mel-
44
litus: relationship to glycaemic control and diabetic complications
. Diabetes Research and Clinical Practice , 1996
; 33(2) : 105-110.
15. Haffner SM, Morales PA, Stern MP, Gruber MK. Lp(a)
concentrations in NIDDM. Diabetes. 1992 ; 41(10) :1267-
72.
16. Chang C J , Kao J T ,Wu T J, Lu F H and Tai T Y. Se- Se-
rum lipids and lipoprotein (a) concentrations in Chinese
NIDDM patients. Relation to metabolic control. Diabetes
Care. 1995 ; 18(8) : 1191-4.
17. G .Utterman, H.J.Menzel, H.G.Kraft, HC Duba, H.G.
Kemmler, and C Seitz. Lp(a) Glycoprotein phenotypes:
Inheritance and relation to Lp(a)- lipoprotein Concentrations
in Plasma. J.Clin. Invest. 1987;80 : 458-465.
18. Pamela J. Schreiner, Gerado Heiss , H.A. Tyroler , Joel D.
Morrisett , C.E. Davis , Robert Smith . Race and Gender
Differences in the Association of Lp(a) With Carotid Artery
Wall Thickness. Arteriosclerosis , Thrombosis , and
Vascular Biology. 1996 ; 16 : 471- 478.
19. Spencer A. Brown , Joel Morrisett , Josef R. Patsch ,
Rebecca Reeves, Antonio M. Gotto ,Jr*., and Wolfgang
Patsch . Influence of short term dietary cholesterol and
fat on human plasma Lp[a] and LDL levels. J . Lipid Res.
1991 ; 32 : 1281 -1289 .
20. David Crook , Mandeep Sidhu , Mary Seed , Martina O’
Donnell, John C .Stevenson. Lipoprotein Lp(a) levels are
reduced by danazol , an anabolic steroid. Athersclerosis .
1992 ; 92(1) : 41- 47.
21. Peter Henriksson , Bo Angelin , and Lars Berglund . Hormonal
Regulation of Serum Lp(a) levels : Opposite Effects
after Estrogen Treatment and Orchidectomy in Males with
Prostatic Carcinoma.J. Clin. Invest .1992 ; 89 : 1166 –
1171.
22. Calmarza F, Vella J C . Lipids, Lipoproteins and apolipo- apolipo-
protein (a) isoforms in type 2 diabetic patients. J Cardiovas
Risk 1999; 6(3): 171 – 5.
23. Ali AlBahrani, Mohammed Alkindi, Eileen Marks, Said
AlYahyaee and Alan Shenkin. Lipoprotein(a): an independent
risk factor for ischemic heart disease that is dependent
on triglycerides in subjects with type 2 diabetes mellitus.
Lipids in Health and Disease 2007 ; 6: 26.
24. Agathoklis Psyrogiannis, Ioannis Habeos, and Venetsana
Kyriazopoulou. Insulin sensitivity and Lp(a) concentrations
in normoglycemic offspring of type2 diabetic parents.
Lipids Health Dis. 2003 ; 2:8.
25. Cristina Hernandez , Pilar Chacon, Luis Garcia- Pascual
and Rafael Simo. Differential Influence of LDL-Cholesterol
and Triglycerides on Lipoprotein(a) Concentrations
in Diabetic patients. Diabetes care 2001 ; 24(2): 350-355.
26. Sandholzer C , Feussner G , Brunzell J, Utermamn G.
Distribution of Apolipoprotein(a) in the Plasma from Patients
with Lipoprotein Lipase Deficiency and with Type
III hyperlipidaemia. No evidence for triglyceride rich precursor
lipoprotein (a). J.Clin. Invest. 1992 ; 90(5):1958
– 1965.
27. Ko SH, Song KH, Ahn YB , Yoo SJ, Son HS, Yoon K H.
The effect of rosiglitazone on serum Lp(a) levels in Korean
patients with type 2 diabetes. Metabolism 2003 ; 52(6) :
731 – 4.
www.biomedicineonline.org Biomedicine - Vol 31; No.1: 2011